Evaxion: Positive Results with Moderna’s and Merck’s Personalised Cancer Vaccine - Redeye

Redeye comments on the positive results in the phase IIb melanoma trial with Moderna’s and Merck’s mRNA-4157/V940, a personalised mRNA cancer vaccine, which is similar to Evaxion’s vaccines. We discuss how this affects our view of Evaxion’s candidates.

Länk till analysen i sin helhet: https://www.redeye.se/research/868665/evaxion-positive-results-with-modernas-and-mercks-personalised-cancer-vaccine?utm_source=finwire&utm_medium=RSS